# Step Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/step-pharma

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.step-ph.com
- Total disclosed funding: $61M
- Latest round: Series C (Oct 15, 2025)
- Investors on record: 8

## About

Step Pharma SAS, based in France, is a biotechnology company focused on developing innovative oncology therapies. Their primary product, dencatistat (STP938), is designed to treat various cancer types with targeted therapy. Founded in 2014 and headquartered in Paris, France, Step Pharma is dedicated to advancing cancer treatment through the development of specialized therapies. In October 2025, Step Pharma raised EUR 38 million in series C funding led by new investor V-Bio Ventures, with participation from returning investors Pontifax Venture Capital, Bpifrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures, and Inserm Transfert Initiative. Step Pharma specializes in the development of innovative oncology therapies, with dencatistat (STP938) as their lead asset. This first-in-class, highly selective, and orally bioavailable targeted therapy aims to address several cancer types, including T Cell Lymphomas, B Cell Lymphomas, Solid Tumors, Essential Thrombocythaemia, and Autoimmune Diseases. By targeting specific pathways involved in cancer cell proliferation, dencatistat seeks to enhance existing treatment regimens. The company's primary market includes healthcare providers and institutions across Europe, particularly in France, Germany, and the United Kingdom, where the demand for novel cancer therapies is significant.Step Pharma generates revenue through strategic partnerships and collaborations with healthcare institutions and pharmaceutical companies in the oncology sector. Their business model includes direct supply agreements with hospitals and clinics utilizing dencatistat and potentially other pipeline products. While specific pricing strategies for dencatistat have not been disclosed, their revenue approach underscores the significance of establishing partnerships that ensure access to their therapeutics for a broader patient population. Step Pharma will use the October 2025 funding to repay senior secured loans, cover outstanding liabilities, and support operating cash needs until the deal closes.

## Funding rounds

- Series C, Oct 15, 2025, $23M — Pontifax Venture Capital, Kurma Partners, Inserm Transfert Initiative, Bpifrance Investissement, Hadean Ventures, V-Bio Ventures, Sunstone Life Science Ventures
- Series B, Jan 15, 2024, $9.9M — Pontifax Venture Capital, Kurma Partners, Bpifrance Investissement, Hadean Ventures, Sunstone Life Science Ventures
- Series B, Oct 20, 2022, $13M — Pontifax Venture Capital, Kurma Partners, Bpifrance Investissement, Hadean Ventures, Sunstone Life Science Ventures
- Series B, Oct 4, 2021, $7M — Pontifax Venture Capital, Kurma Partners, Bpifrance Investissement, Hadean Ventures, Sunstone Life Science Ventures
- Series B, Mar 23, 2021, $8.3M — Pontifax Venture Capital, Kurma Partners, Bpifrance, Hadean Ventures, Sunstone Life Science Ventures

## Investors

- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B, Series C
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series B, Series C
- Bpifrance — Series B
- Hadean Ventures (https://capitalatlas.ai/funds/hadean-ventures) — Series B, Series C
- Sunstone Life Science Ventures (https://capitalatlas.ai/funds/sunstone-life-science-ventures) — Series B, Series C
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series B, Series C
- Inserm Transfert Initiative (https://capitalatlas.ai/funds/inserm-transfert-initiative) — Series C
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series C